Table 2.
Mean (±standard error) LVEF (%) values according to timing of NPLD, regimen used, and age at diagnosis.
| Baseline | During | ≤4 months after chemotherapy ended | 5–8 months after chemotherapy ended | 9–12 months after chemotherapy ended | >12 months after chemotherapy ended | ||
|---|---|---|---|---|---|---|---|
| NPLD timing | Adjuvant | 63.9 ± 0.7 (n = 60) |
64.8 ± 0.8 (n = 33) |
63.4 ± 1.3 (n = 31) |
64.8 ± 1.7 (n = 11) |
62.8 ± 1.6 (n = 4) |
64.1 ± 1.6 (n = 8) |
| Primary | 65.1 ± 1.3 (n = 17) |
63.0 ± 1.6 (n = 8) |
63.3 ± 1.5 (n = 6) |
63.8 ± 2.8 (n = 6) |
No data | 68.5 ± 1.5 (n = 2) |
|
|
| |||||||
| NPLD regimen | AC + T | 63.8 ± 0.7 (n = 59) |
63.9 ± 0.8 (n = 27) |
63.3 ± 1.3 (n = 29) |
64.7 ± 1.5 (n = 12) |
63.7 ± 1.9 (n = 3) |
64.6 ± 1.7 (n = 7) |
| TAC | 66.1 ± 1.5 (n = 14) |
65.4 ± 1.7 (n = 12) |
63.9 ± 2.0 (n = 7) |
64.0 ± 3.6 (n = 5) |
60.0 (n = 1) |
66.0 ± 3.1 (n = 3) |
|
| AC | 62.7 ± 2.7 (n = 3) |
66.0 ± 2.0 (n = 2) |
60.0 (n = 1) |
No data | No data | No data | |
|
| |||||||
| Age at diagnosis | <60 | 64.0 ± 0.8 (n = 53) |
65.1 ± 0.8 (n = 29) |
62.9 ± 1.5 (n = 25) |
64.0 ± 1.6 (n = 15) |
62.8 ± 1.6 (n = 4) |
64.9 ± 1.6 (n = 8) |
| ≥60 | 64.5 ± 1.0 (n = 23) |
62.8 ± 1.6 (n = 12) |
64.3 ± 1.4 (n = 12) |
68.0 ± 2.0 (n = 2) |
No data | 64.5 ± 2.5 (n = 2) |
|
AC: 6 cycles of NPLD (60 mg/m2) and cyclophosphamide (600 mg/m2).
AC + T: 4 cycles of NPLD (60 mg/m2) and cyclophosphamide (600 mg/m2) followed by 4 cycles of docetaxel (75 mg/m2).
TAC: six cycles of NPLD (60 mg/m2) and cyclophosphamide (600 mg/m2) and docetaxel (75 mg/m2).